Pasithea Therapeutics Corp.
KTTA
$1.19
-$0.02-1.65%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -34.25% | -11.85% | 8.28% | -32.34% | -16.00% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -20.71% | 3.04% | 25.78% | 27.36% | -1.72% |
| Operating Income | 20.71% | -3.04% | -25.78% | -27.36% | 1.72% |
| Income Before Tax | 16.96% | -7.45% | -18.22% | -24.12% | 13.80% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 16.96% | -7.45% | -18.22% | -24.12% | 13.80% |
| Earnings from Discontinued Operations | -- | -- | -- | 98.41% | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 16.96% | -2.74% | -9.13% | 1.36% | 21.23% |
| EBIT | 20.71% | -3.04% | -25.78% | -27.36% | 1.72% |
| EBITDA | 21.64% | -3.17% | -27.13% | -23.47% | 5.52% |
| EPS Basic | -0.05% | -28.64% | -36.47% | -19.16% | 16.88% |
| Normalized Basic EPS | -0.05% | -34.55% | -47.84% | -103.53% | 9.05% |
| EPS Diluted | -0.05% | -28.64% | -36.47% | -19.16% | 16.88% |
| Normalized Diluted EPS | -0.05% | -34.55% | -47.84% | -103.53% | 9.05% |
| Average Basic Shares Outstanding | -17.01% | -20.14% | -20.04% | -2.83% | -5.22% |
| Average Diluted Shares Outstanding | -17.01% | -20.14% | -20.04% | -2.83% | -5.22% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
